Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rezatomidine SCHEMBL345466 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Rezatomidine SCHEMBL29376551 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Rezatomidine SCHEMBL7799658 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL14546567 | 0.84 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL8510869 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL8510363 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3709658 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3749391 | 0.78 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3418059 | 0.78 | CYP1A2 (0.45) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3419587 | 0.78 | CES2 (0.33) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248929-A1 | VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE | EYE THERAPIES LLC (US) | 2025-08-07 | — | — | US | claimed |
| CN-117279939-A | Eye antibody-drug conjugates | ADS医疗有限责任公司 | 2023-12-22 | — | — | CN | claimed |
| US-20230398233-A1 | OCULAR ANTIBODY-DRUG CONJUGATES | ADS THERAPEUTICS LLC (US) | 2023-12-14 | — | — | US | claimed |
| EP-3813793-B1 | A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | ADS THERAPEUTICS LLC (US) | 2023-09-20 | — | — | EP | claimed |
| EP-4240425-A1 | OCULAR ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2023-09-13 | — | — | EP | claimed |
| US-11344538-B2 | Methods for the treatment of myopia | LENZ THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | claimed |
| WO-2022098717-A1 | OCULAR ANTIBODY-DRUG CONJUGATES | ADS THERAPEUTICS LLC (US) | 2022-05-12 | — | — | WO | claimed |
| US-20220031739-A1 | ANTI-VIRAL COMPOSITIONS AND METHODS OF USE THEREOF | EYE THERAPIES LLC | 2022-02-03 | — | — | US | claimed |
| US-20210228574-A1 | A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | ADS THERAPEUTICS LLC | 2021-07-29 | — | — | US | claimed |
| EP-3813793-A1 | A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | Cloudbreak Therapeutics, LLC (US) | 2021-05-05 | — | — | EP | claimed |
| US-20110160214-A1 | Compositions and methods for eye whitening | Alpha Synergy Development, Inc. | 2011-06-30 | — | — | US | claimed |
| US-20110152271-A1 | Compositions and methods for ophthalmic delivery of nasal decongestants | HORN GERALD | 2011-06-23 | — | — | US | claimed |
| WO-2011075621-A1 | COMPOSITIONS AND METHODS FOR OPHTHALMIC DELIVERY OF NASAL DECONGESTANTS | Alpha Synergy Development, Inc. (US) | 2011-06-23 | — | — | WO | claimed |
| US-20100029660-A1 | Compositions and methods for reversing rebound hyperemia | Alpha Synergy Development, Inc. | 2010-02-04 | — | — | US | claimed |
| US-20100028267-A1 | Compositions and methods for reducing capillary permeability | Alpha Synergy Development, Inc. | 2010-02-04 | — | — | US | claimed |
| US-20100029661-A1 | Anesthetic compositions and methods of use | Alpha Synergy Development, Inc. | 2010-02-04 | — | — | US | claimed |
| US-20100029663-A1 | Compositions and methods for reducing activation of alpha-1 receptors | Alpha Synergy Development, Inc. | 2010-02-04 | — | — | US | claimed |
| US-20100028266-A1 | Composition and methods for treating allergic response | Alpha Synergy Development. Inc. | 2010-02-04 | — | — | US | claimed |
| US-20100029659-A1 | Preferential vasoconstriction compositions and methods of use | Alpha Synergy Development,Inc. | 2010-02-04 | — | — | US | claimed |
| US-20100029662-A1 | Vasoconstriction compositions and methods of use | Alpha Synergy Development, Inc. | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398233-A1 | OCULAR ANTIBODY-DRUG CONJUGATES | UACA, CD40, TNFRSF9 | ADRA2A 401/4885ADRA2B 468/4885ADRA2C 725/4885 |
| US-20210228574-A1 | A COMPOSITION FOR TREATING OCULAR HYPEREMIA AND A METHOD FOR TREATING OCULAR HYPEREMIA WITH THE SAME | ADRB1, ADRB2, ADRA1A | ADRA2A 4/4885ADRA2B 6/4885ADRA2C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.